ACE inhibitors and angiotensin receptor blockers (ARB) in prevention of diabetic nephropathy
Last reviewed 04/2023
- Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs) prevent the progression of diabetic nephropathy (DN)
- studies suggest that combination renin-angiotensin-aldosterone system (RAAS)-inhibiting therapy provides additive benefit in DN
- a meta-analysis of studies investigating combination therapy for DN
was undertaken
- meta-analysis suggests that ACEI + ARB reduces 24-h proteinuria to a greater extent than ACEI alone. This benefit is associated with small effects on GFR, serum creatinine, potassium and blood pressure
- results should be interpreted cautiously as most of the included studies were of short duration and the few long-term studies (12 months) have not demonstrated benefit
Reference:
ACE inhibitors and ARBs in the prevention of type 2 diabetes
angiotensin receptor blockers (ARB)
ACE inhibitors and angiotensin receptor blockers (ARB) in heart failure
ACE inhibitors and angiotensin receptor blockers (ARB) in patients at high risk of vascular disease